Rocuronium Bromide injection is used as a supplement to general anesthesia to help with tracheal intubation and to relax skeletal muscles during surgery or mechanical ventilation.

Anesthesia

• To be administered only by experienced clinicians or adequately trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. 
• Individualize the dose for each patient. 
• Peripheral nerve stimulator recommended for determination of drug response and need for additional doses, and to evaluate recovery. 
• Tracheal intubation: Recommended initial dose is 0.6 mg/kg
• Rapid sequence intubation: 0.6 to 1.2 mg/kg
• Maintenance doses: Guided by response to prior dose, not administered until recovery is evident.
• Continuous infusion: Initial rate of 10 to 12 mcg/kg/min. Start only after early evidence of spontaneous recovery from an intubating dose.

The following side effects may occur with the use of Rocuronium-

• Salivation
• Rashes
• Bronchospasm
• Flushing
• Hypotension
• Tachycardia

Excessive salivation

Rash

Broncho Spasm

Flushing

• Appropriate Administration and Monitoring: Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available.
• Anaphylaxis: Severe anaphylaxis has been reported. Consider cross-reactivity among neuromuscular blocking agents.
• Need for Adequate Anesthesia: Must be accompanied by adequate anesthesia or sedation.
• Residual Paralysis: Consider using a reversal agent in cases where residual paralysis is more likely to occur.